This is a working overview of Fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
== Other notable isomers == Holmium's nuclear isomer 166m167Ho has a half-life of 1,133 years, which is nearly the longest half-life of any holmium radionuclide. Only 163Ho, with a half-life of 4,570 years, is more stable. Both the excitation energy of the former, and the decay energy of the latter, are less than 10 keV. 229m90Th is a remarkably low-lying metastable isomer, only 8.355733554021(8) eV above the ground state. This low energy produces light at a wavelength of 148.3821828827(15) nm, in the far ultraviolet instead of the typical gamma ray band. This allows for direct nuclear laser spectroscopy. Such ultra-precise spectroscopy, however, could not begin without a sufficiently precise initial estimate of the wavelength, something that was only achieved in 2024 after two decades (from 2003 to 2024) of effort. The energy is so low that the ionization state of the atom affects its half-life. Neutral 229m90Th decays by internal conversion with a half-life of 7±1 μs, but because the isomeric energy is less than thorium's second ionization energy of 11.5 eV, this channel is forbidden in thorium cations and 229m90Th+ decays by gamma emission with a half-life of 1740±50 s. This conveniently moderate lifetime allows the development of a nuclear clock of unprecedented accuracy.
== Early life == Peters was born Braden Eric Peters to a businessman father and stay-at-home mother. He was raised in Hoboken, New Jersey, and attended Seton Hall Preparatory School in West Orange, New Jersey. He has stated that he became interested in looksmaxxing—a term originating on incel message boards in the early 2010s that describes the process of making oneself as physically attractive as possible—in high school, which he has attributed to wanting to influence others politically by becoming more attractive. Peters described his life during the COVID-19 lockdowns as being "online for 14 hours a day", browsing looksmaxxing forums, playing Grand Theft Auto V and skipping online classes. Peters has stated in interviews that he would often hide his testosterone supplements from his parents, and when caught, he would be sent to live with his grandmother. Peters claims to have been expelled after "just three weeks" from Sacred Heart University in Fairfield, Connecticut for his use of "peptides and 'roids".
Nicotine is a stimulant and alkaloid found primarily in plants of the nightshade family, notably in tobacco; it is also synthesized. Nicotine is used recreationally for its stimulant and anxiolytic effects. In tobacco leaves, nicotine constitutes about 0.6–3% of the dry weight, and smaller, trace quantities occur in other Solanaceae crops such as tomatoes, potatoes, and eggplants. In pure form, nicotine is a colorless to yellowish, oily liquid that readily penetrates biological membranes and acts as a potent neurotoxin in insects, where it serves as an antiherbivore toxin. Historically, it was widely used as an insecticide, and its structure provided the basis for synthetic neonicotinoid pesticides. In humans, nicotine acts primarily as a stimulant by binding to and activating nicotinic acetylcholine receptors (nAChRs) in the central nervous system and peripheral tissues. This results in the release of neurotransmitters such as dopamine, acetylcholine, and norepinephrine, producing effects including increased alertness, reduced anxiety, and mild euphoria. Nicotine is typically consumed through tobacco smoking, vaping, or other nicotine delivery systems. An average cigarette yields about 2 mg of absorbed nicotine, a dose sufficient to produce reinforcement and dependence while remaining far below toxic levels. Nicotine is highly addictive, and nicotine dependence is characterized by tolerance, physical dependence, psychological dependence, and nicotine withdrawal symptoms such as irritability, anxiety, and difficulty concentrating.
== Prevalence and health effects == Lignans are the principal source of dietary phytoestrogens in typical Western diets, even though most research on phytoestrogen-rich diets has focused on soy isoflavones. Lignan's enterolignan products enterodiol and enterolactone have weak estrogenic activity, but they may also exert biological effects through non-estrogenic means. A 2021 review found that lignans have a positive effect on lipid profiles of patients with dyslipidemia related diseases. As of 2022, there is limited evidence that dietary intake of lignans is associated with a reduced cancer and cardiovascular disease risk.
Sources: en.wikipedia.org
== Opioid replacement therapy == According to a Cochrane review in 2013, extended-release morphine as an opioid replacement therapy for people with heroin addiction or dependence confers a possible reduction of opioid use and with fewer depressive symptoms but overall more adverse effects when compared to other forms of long-acting opioids. The length of time in treatment was not found to be significantly different.
According to a report submitted to the Japanese Pharmaceuticals and Medical Devices Agency regarding Glanatec, ripasudil hydrochloride hydrate showed no binding affinity for receptors of the adrenergic, angiotensin II, endothelin, glutamate, histamine, muscarinic, or prostanoid variety. This lack of affinity also applies to Ca2+ and K+ channels, carbonic anhydrase, and HMG-CoA reductase. Toxicity information is compiled in the following tables.
== Since November 2022 == On April 20, 2023, Twitter (known as X since July 2023) began removing verification status for users of public interest, causing a controversy among Twitter users. The website's system was altered, allowing any individual to receive verification for a monthly fee, an act which saw significant criticism. Following the acquisition of Twitter by Elon Musk on October 28, 2022, Musk told Twitter employees to introduce paid verification by November 7 through Twitter Blue. The Verge reported that the updated Blue subscription would cost $19.99 per month, and users would lose their verification status if they did not join within 90 days. Following backlash, Musk tweeted, in response to author Stephen King, a lowered $8 price on November 1, 2022. Twitter confirmed the new price of $7.99 per month on November 5, 2022. The new verification system began rollout on November 9, 2022, a day after the 2022 United States elections. The decision to delay its rollout was to address concerns about users potentially spreading misinformation about voting results by posing as news outlets and lawmakers. At the same time, Twitter introduced a secondary gray "Official" label on some high-profile accounts, but removed them hours after launch. Less than 48 hours later, Twitter reinstated the gray "Official" label, after multiple users were suspended for deliberately impersonating reporters and high-profile athletes like LeBron James.
== Transition from plaque induced gingivitis to periodontitis == Plaque-induced gingivitis and the more severe stage plaque induced periodontitis are the most common of the periodontal diseases. While in some individuals gingivitis never progresses to periodontitis, periodontitis is always preceded by gingivitis. In 1976, Page & Schroeder introduced an innovative new analysis of periodontal disease based on histopathologic and ultrastructural features of the diseased gingival tissue. Although this new classification does not correlate with clinical signs and symptoms and is admittedly "somewhat arbitrary," it permits a focus of attention pathologic aspects of the disease that were, until recently, not well understood. This new classification divided plaque-induced periodontal lesions into four stages, namely, initial lesion, early lesion, established lesion and advanced lesion.
Sources: en.wikipedia.org
=== Superabsorbent polymers === One area of aspartic acid market growth is biodegradable superabsorbent polymers (SAP), and hydrogels. Around 75% of superabsorbent polymers are used in disposable diapers and an additional 20% is used for adult incontinence and feminine hygiene products. Polyaspartic acid, the polymerization product of aspartic acid, is a biodegradable substitute to polyacrylate.
{\displaystyle {\begin{aligned}[][a_{0},a_{1},a_{2},a_{3}]&=[0.616634218997,0.108855827811,0.023453835635,0.000449332509]\\[][b_{1},b_{2},b_{3},b_{4},b_{5},b_{6}]&=[1.919948267476,1.635304362591,0.799392556572,0.240278859212,0.043178653945,0.003863334276]\end{aligned}}}
Having "engaged in practices that exposed players to significant risks to their health and safety as well as the risk of using substances that were prohibited by the AFL Anti-Doping Code and the World Anti-Doping Code". Allowing "a culture of frequent, uninformed and unregulated use of the injection of supplements" at the club. Had "failed to meaningfully inform players of the substances the subject of the program and obtain their informed consent to the administration of the substances". Having an incomplete record-keeping system made it impossible to determine with certainty whether or not players had been administered banned supplements. The bypassing of human resources practices relating specifically to the employment of Robinson and Dank. The interim report found that Essendon had intended the program to be an innovative program of unprecedented scale to deliver a competitive edge to the club, but that it had not done adequate research nor established clear lines of accountability for those implementing the program. The AFL Tribunal later commented that there was a "deplorable absence of records in the program relating to its administration." Essendon and the AFL discussed and negotiated penalties for the charges over two days in August. On 27 August 2013, five days before the final round of the 2013 home-and-away season, the following penalties were agreed to and imposed:
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.